ethyl 3-ethoxy-2-(2,4,5-trifluoro-3-methoxybenzoyl)acrylate | 122375-85-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 3-ethoxy-2-(2,4,5-trifluoro-3-methoxybenzoyl)acrylate
• 英文别名: ethyl 3-ethoxy-2-(2,4,5-trifluoro-3-methoxybenzoyl)prop-2-enoate
• CAS: 122375-85-3
• 化学式: C₁₅H₁₅F₃O₅
• 分子量: 332.276
• InChiKey: ZIMIAPVHHUISPY-UHFFFAOYSA-N

物化性质

• 沸点：
  431.6±45.0 °C(Predicted)
• 密度：
  1.278±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  ethyl 3-ethoxy-2-(2,4,5-trifluoro-3-methoxybenzoyl)acrylate 在 盐酸 、 硫酸 、 水 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 甲醇 、 乙醇 、 水 、 溶剂黄146 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 14.0h， 生成 7-(3-amino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
  参考文献：
  名称：

  8-alkoxyquinolonecarboxylic acid and salts thereof

  摘要：

  喹诺酮羧酸衍生物的化学式如下：##STR1## 其中 R 表示氢原子或较低的烷基基团，R.sup.1 表示较低的烷基基团，R.sup.2 表示氢原子、氨基团或硝基团，X 表示卤素原子，Z 表示卤素原子、哌嗪基团、N-甲基哌嗪基团、3-甲基哌嗪基团、3-羟基吡咯啉基团或吡咯啉基团，如下所示：##STR2##（这里，n 为 0 或 1，R.sup.3 表示氢原子或较低的烷基基团，R.sup.4 表示氢原子、较低的烷基基团，R.sup.5 表示氢原子、较低的烷基基团、酰基基团或烷氧羰基基团），其水合物和药学上可接受的盐被用作抗菌剂。

  公开号：

  US04980470A1
• 作为产物：
  描述：

  3-甲氧基-2,4,5-三氟苯甲酸 在 氯化亚砜 、 magnesium ethylate 、 乙酸酐 、 对甲苯磺酸 作用下， 以 水 、 甲苯 为溶剂， 反应 23.0h， 生成 ethyl 3-ethoxy-2-(2,4,5-trifluoro-3-methoxybenzoyl)acrylate
  参考文献：
  名称：

  8-alkoxyquinolonecarboxylic acid and salts thereof

  摘要：

  喹诺酮羧酸衍生物的化学式如下：##STR1## 其中 R 表示氢原子或较低的烷基基团，R.sup.1 表示较低的烷基基团，R.sup.2 表示氢原子、氨基团或硝基团，X 表示卤素原子，Z 表示卤素原子、哌嗪基团、N-甲基哌嗪基团、3-甲基哌嗪基团、3-羟基吡咯啉基团或吡咯啉基团，如下所示：##STR2##（这里，n 为 0 或 1，R.sup.3 表示氢原子或较低的烷基基团，R.sup.4 表示氢原子、较低的烷基基团，R.sup.5 表示氢原子、较低的烷基基团、酰基基团或烷氧羰基基团），其水合物和药学上可接受的盐被用作抗菌剂。

  公开号：

  US04980470A1

文献信息

• NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF
  申请人：WAKUNAGA PHARMACEUTICAL CO., LTD.

  公开号：US20190276407A1

  公开（公告）日：2019-09-12

  A pyridonecarboxylic acid derivative or a salt thereof is represented by Formula (1), where R 1 is hydrogen, a halogen atom, a lower alkyl group, or an amino group; R 2 is —NH—R 6 , where R 6 is hydrogen, a lower alkyl group, an amino lower alkyl group, or the like; —O—R 7 , where R 7 is hydrogen, a lower alkyl group, or the like; —(CH 2 ) m —R 8 , where R 8 is an amino group or the like, m is 1, 2, 3 or 4; or a cyclic amino group of Formula (2), where Y represents NH or C—R 9a R 9b , where R 9a and R 9b are each independently hydrogen, a lower alkyl group, an amino group, a lower alkyl amino group, or the like; n and p are 1 or 2; R 3 is hydrogen, a halogen atom, a lower alkyl group, or the like; R 4 is hydrogen or a carboxyl group-protecting group; and R 5 is hydrogen or a hydroxyl group-protecting group.

  化合物或其盐可由以下式（1）表示，其中R1是氢、卤素原子、低烷基或氨基；R2是—NH—R6，其中R6是氢、低烷基、氨基低烷基或类似物；—O—R7，其中R7是氢、低烷基或类似物；—(CH2)m—R8，其中R8是氨基或类似物，m为1、2、3或4；或由以下式（2）的环状氨基团表示，其中Y代表NH或C—R9aR9b，其中R9a和R9b各自独立地是氢、低烷基、氨基、低烷基氨基或类似物；n和p为1或2；R3是氢、卤素原子、低烷基或类似物；R4是氢或羧基保护基团；R5是氢或羟基保护基团。
• 1,4-dihydro-4-oxo-3-quinoline derivatives as selectively toxic mammalian
  申请人：Pfizer Inc.

  公开号：US05385913A1

  公开（公告）日：1995-01-31

  Compounds of the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein Q, X and R are as defined below. The compounds of formula I are broad spectrum mammalian antibacterial agents and exhibit favorable selectivity against procaryotic cells.

  化合物的公式为##STR1##和其药学上可接受的盐，其中Q、X和R的定义如下。公式I的化合物是广谱哺乳动物抗菌剂，并对原核细胞表现出良好的选择性。
• The Synthesis, Structure-Activity, and Structure-Side Effect Relationships of a Series of 8-Alkoxy- and 5-Amino-8-alkoxyquinolone Antibacterial Agents
  作者：Joseph P. Sanchez、Rocco D. Gogliotti、John M. Domagala、Stephen J. Gracheck、Michael D. Huband、Josephine A. Sesnie、Michael A. Cohen、Martin A. Shapiro

  DOI：10.1021/jm00022a013

  日期：1995.10

  A series of 1-cyclopropyl-6-fluoro-8-alkoxy (8-methoxy and 8-ethoxy)-quionoline-3-carboxylic acids and 1-cyclopropyl-5-amino-6-fluoro-8-alkoxyquinoline-3-carboxylic acids has been prepared and evaluated for antibacterial activity. In addition, they were also compared to quinolones with classic substitution at C-8 (H, F, Cl) and the naphthyridine nucleus in a phototoxicity and mammalian cell cytotoxicity assay. The series of 8-methoxyquinolones had antibacterial activity against Gram-positive, Gram-negative, and anaerobic bacteria equivalent to the most active 8-substituted compounds (8-F and 8-Cl). There was also a concomitant reduction in several of the potential side effects (i.e., phototoxicity and clonogenicity) compared to the most active quinolones with classic substitution at C-8. The 8-ethoxy derivatives had an even better safety profile but were significantly less active (2-3 dilutions) in the antibacterial assay.
• Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety
  作者：Hongmin Liu、Ju Huang、Jiayang Wang、Minghua Wang、Mingliang Liu、Bin Wang、Huiyuan Guo、Yu Lu

  DOI：10.1016/j.ejmech.2014.09.029

  日期：2014.10

  A series of novel 1-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives 9a-d containing an oxime functional moiety were synthesized and evaluated for their biological activity. Our results reveal that 9a1 and 9b3 have good in vitro activity against MTB H37Rv ATCC 27294 (MIC: 0.25 mu g/mL) and two MDR-MTB clinical isolates (MICs: 0.065-0.125 mu g/mL). Most of 9a-d show potent activity against Escherichia coli and Klebsiella pneumoniae (MICs: <0.008-4 mu g/mL) except extended-spectrum beta-lactamase-producing strains. Especially, 9a1 and 9d4 possessing excellent in vitro activity against all of the fourteen Gram-positive strains including MRSA and MRSE (MICs: <0.008-2 mu g/mL) comparable to or better than the four reference drugs, show considerable in vivo efficacy against five Gram-negative and Gram-positive isolate strains (ED(50)s: 11.43-26.04 mg/kg). (C) 2014 Elsevier Masson SAS. All rights reserved.
• Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids
  作者：Palaniappan Senthilkumar、Murugesan Dinakaran、Debjani Banerjee、Ruth Vandana Devakaram、Perumal Yogeeswari、Arnab China、Valakunja Nagaraja、Dharmarajan Sriram

  DOI：10.1016/j.bmc.2007.11.050

  日期：2008.3

  Thirty-four newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids were synthesized from 1,2,3,4-tetrafluoro benzene and evaluated for in vitro and in vivo antimycobacterial activities against Mycobacterium tuberculosis H37Rv (MT13), multi-drug resistant M. tuberculosis (MDR-TB) and Mycobacterium sinegmatis (MC2) and also tested for the ability to inhibit the supercoiling activity of DNA gyrase. Among the synthesized compounds, 7-(1-(4-methoxybenzyl)-3,4,5,6,7,8-hexahydroisoquinolin-2(1H)-yl)-1-cyclopropy1-6-fluoro-1,4-dihydro-8-methoxy-5-nitro-4-oxoquinoline-3-carboxylic acid (13n) was found to be the most active compound in vitro with MIC of 0.16 and 0.33 mu M against MT13 and MDR-TB, respectively. In the in vivo animal model 13n decreased the bacterial load in lung and spleen tissues with 2.54 and 2.92 - log 10 protections, respectively, at the dose of 50 mg/kg body weight. Compound 13n also inhibited the supercoiling activity of mycobacterial DNA gyrase with IC50 of 30.0 mu g/ml. (C) 2007 Elsevier Ltd. All rights reserved.